生物制药公司Scholar Rock Holding Corporation（SRRK）今日盘中大跌18.70%，引发投资者关注。该公司最新公布的季度业绩显示亏损扩大，远超分析师预期，成为股价下跌的主要原因。
根据公司公告，Scholar Rock截至6月30日的季度调整后每股亏损为0.98美元，显著高于去年同期的0.60美元亏损。这一数字也远超过分析师平均预期的0.66美元亏损。公司当季总亏损达1.103亿美元，而收入仍为零。这一业绩表现大大低于华尔街的预期，导致投资者信心受挫。
值得注意的是，过去三个月内，分析师对该公司的盈利预期已下调约3.5%。尽管如此，多数分析师仍对Scholar Rock保持乐观态度，目前平均评级为"买入"。然而，这次远低于预期的季度业绩可能会引发分析师重新评估其未来前景。在生物技术行业竞争激烈的环境下，Scholar Rock面临着将其研发成果转化为实际收入的压力。投资者将密切关注公司后续的业务进展和财务状况改善情况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.